EpilepsyGTx is a late-stage biotech company exploring cutting-edge gene therapies to improve the management of focal refractory epilepsy.
EpilepsyGTx has raised $33.0M in total funding. The most recent round was Series A. The last funding was announced in December 2025.
EpilepsyGTx's investors include British Business Bank, XGEN Venture, UCL Technology Fund, HTH.
EpilepsyGTx is headquartered in Canterbury, United Kingdom.
EpilepsyGTx is a late-stage biotech company exploring cutting-edge gene therapies to improve the management of focal refractory epilepsy.
EpilepsyGTx is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"EpilepsyGTx — Funding & Investors." VCBacked, December 10, 2025, https://www.vcbacked.co/company/epilepsygtx. Accessed September 3, 2026.
VCBacked. (2025). EpilepsyGTx — Funding & Investors. Retrieved September 3, 2026, from https://www.vcbacked.co/company/epilepsygtx
{{cite web |title=EpilepsyGTx — Funding & Investors |url=https://www.vcbacked.co/company/epilepsygtx |website=VCBacked |access-date=September 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated